NUVB is trading 5.3% up at $5.91 after announcing an upsized $250 million convertible senior notes offering.
- The sale is expected to close on June 30, 2026, with investors reacting to the capital raise terms and implied conversion premium versus recent prices.
- Market sentiment is also bolstered by recent regulatory progress for taletrectinib, Nuvation Bio’s lead drug candidate for lung cancer.